Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Behrad Derakhshan sold 1,718 shares of Edgewise Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $32,487.38. Following the transaction, the insider now directly owns 13,422 shares in the company, valued at approximately $253,810.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Behrad Derakhshan also recently made the following trade(s):
- On Thursday, February 8th, Behrad Derakhshan sold 4,600 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $20.01, for a total value of $92,046.00.
Edgewise Therapeutics Stock Performance
EWTX stock opened at $19.52 on Friday. The stock has a fifty day moving average of $16.90 and a 200-day moving average of $12.73. Edgewise Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $20.90. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -12.35 and a beta of 0.15.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.03). Equities analysts predict that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.
Institutional Trading of Edgewise Therapeutics
Urgent Nvidia Warning
From Altimetry | Ad
Could Steve Job's 'Final Prophecy' Make You Rich?
Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
Click here to access…
Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Edgewise Therapeutics by 349.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company's stock valued at $80,000 after buying an additional 5,704 shares during the period. AJOVista LLC purchased a new position in Edgewise Therapeutics during the fourth quarter valued at approximately $84,000. Pale Fire Capital SE bought a new stake in Edgewise Therapeutics during the 3rd quarter worth approximately $90,000. Corton Capital Inc. purchased a new stake in Edgewise Therapeutics in the 3rd quarter worth approximately $98,000. Finally, SG Americas Securities LLC bought a new position in Edgewise Therapeutics in the 3rd quarter valued at $107,000.
Analyst Ratings Changes
EWTX has been the topic of several research analyst reports. Royal Bank of Canada boosted their price objective on Edgewise Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, April 22nd. Wedbush restated an "outperform" rating and set a $26.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday, April 16th. Truist Financial reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, April 17th. Finally, Piper Sandler started coverage on shares of Edgewise Therapeutics in a research report on Thursday, March 7th. They set an "overweight" rating and a $48.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Edgewise Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $31.20.
Get Our Latest Report on EWTX
Edgewise Therapeutics Company Profile
(
Get Free Report)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
